氟[¹⁸F]贝他苯(Florbetaben F-18) - 药物靶点：APP_在研适应症：阿尔茨海默症，认知功能障碍，诊断试剂_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

florbetaben (18F)、Florbetaben [¹⁸F]、氟比他班 F18

+ [8]

靶点

APP

作用方式

抑制剂

作用机制

APP抑制剂(β-淀粉状蛋白A4抑制剂)

治疗领域

神经系统疾病其他疾病肿瘤+ [4]

在研适应症

阿尔茨海默症认知功能障碍诊断试剂+ [3]

非在研适应症

脑淀粉样血管病唐氏综合征额颞痴呆+ [2]

原研机构

Piramal Pharma Limited

在研机构

Lantheus Holdings, Inc.

北京先通国际医药科技股份有限公司Lantheus Medical Imaging, Inc.

+ [1]

非在研机构

Life Molecular Imaging GmbH (Germany)Life Molecular Imaging Ltd.

权益机构

PharmaLogic Holdings Corp.

Lantheus Holdings, Inc.士宣生物科技（上海）有限公司

+ [5]

最高研发阶段批准上市

首次获批日期

欧盟 (2014-02-20),

认知功能障碍诊断试剂

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C21H26FNO3

InChIKeyNCWZOASIUQVOFA-FWZJPQCDSA-N

CAS号902143-01-5

关联

52

项与氟[¹⁸F]贝他苯相关的临床试验

NCT07624760

/ Not yet recruitingN/AIIT

Early Detection of Light-Chain Amyloidosis in Monoclonal Gammopathy Using 18F-Florbetaben PET/MR: a Prospective, Single-Center, Observational Study

The goal of this clinical trial is to evaluate whether ¹⁸F-florbetaben PET/MR can detect systemic amyloid deposits early and noninvasively in patients with monoclonal gammopathy. The main question it aims to answer is: Can ¹⁸F-florbetaben PET/MR identify systemic amyloid deposits across clinically and histologically defined patient groups?
Participants will:
* Be screened for eligibility and asked to sign an informed consent form
* Have their vital signs measured
* Receive a single intravenous injection of approximately 300 MBq ¹⁸F-florbetaben (Neuraceq®), followed by whole-body PET/MR imaging from skull base to below the kidneys. If MRI is contraindicated (e.g., pacemaker, severe claustrophobia), PET/CT will be performed instead. The scan takes approximately one hour, during which participants lie still in the scanner
* Be monitored during and after the scan for any side effects or adverse events
* Complete study participation at the end of the imaging session (single visit, no follow-up required)

开始日期2026-10-01

申办/合作机构

University of Zurich

NCT07169630

/ Recruiting临床1期IIT

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)

Background:
About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI.
Objective:
To test whether medical imaging using a new radiotracer ([18F]PF-06445974) can measure PDE4B in the brains of people with AD or MCI.
Eligibility:
People aged 50 years and older with AD or MCI. Healthy volunteers are also needed.
Design:
Participants will have up to 5 clinic visits with 3 imaging scans of the brain.
They will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory.
Participants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each.
Participants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 hours....

开始日期2026-09-09

申办/合作机构

National Institute of Mental Health

NCT07787169

/ Not yet recruiting临床1期

A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the Treatment of Alzheimer's Disease

The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein (amyloid plaque) in the brain in participants with Alzheimer's Disease. Participants will enroll into either A1D-MC-AT01 (NCT07787182) or A1D-MC-AT02 (upcoming).

开始日期2026-09-01

申办/合作机构

Eli Lilly & Co.

100 项与氟[¹⁸F]贝他苯相关的临床结果

登录后查看更多信息

100 项与氟[¹⁸F]贝他苯相关的转化医学

登录后查看更多信息

100 项与氟[¹⁸F]贝他苯相关的专利（医药）

登录后查看更多信息

217

项与氟[¹⁸F]贝他苯相关的文献（医药）

2026-05-01·JPAD-Journal of Prevention of Alzheimers Disease

Discordance in amyloid positivity between visual reads and Centiloids: Impact of white matter uptake

Article

作者: Devanarayan, Viswanath ; Charil, Arnaud ; Reyderman, Larisa ; Kramer, Lynn D ; Irizarry, Michael C ; Reilhac, Anthonin ; Dhadda, Shobha ; Nelson, Todd M

BACKGROUND:

The visual interpretation of amyloid PET scans, or visual read (VR), is the most common technique used in clinical practice to identify the presence of cerebral amyloid plaques. Amyloid status (positive or negative) determined by VR or using a Centiloid (CL) cut-off shows high overall concordance. However, discordant cases can occur where the VR is positive, but the CL is below the positivity cut-off, or vice versa.

OBJECTIVES:

The objective of this analysis was to evaluate the rate of discordance and explore potential causes, particularly the role of amyloid tracer uptake in the white matter (WM), when determining amyloid status using VR and CL in screening for the elenbecestat phase 3 studies in early Alzheimer's disease (AD).

DESIGN:

Amyloid PET scans using either Florbetapir (Amyvid™), Florbetaben (Neuraceq™) or Flutemetamol (Vizamyl™) from 3,232 participants (1507 VR- and 1725 VR+) with cognitive impairment screened for the elenbecestat phase 3 studies in early AD were visually interpreted at screening by trained neuroradiologists and quantified using CL values.

SETTING:

Academic and clinical centers INTERVENTION/MEASUREMENTS: Quantitatively, amyloid positivity was defined as CL > 32.21. The number of positive cortical regions was determined by counting the number of regions with a standardized uptake value ratio (SUVr) that exceeded 1.17. PET SUVr levels in the cerebral WM were measured using an eroded WM region of interest (ROI). Statistical tests were conducted to detect differences among the four concordance groups, defined by the relationship of VR and CL status (positive or negative). Additionally, tests examined the relationship between uptake in the WM and rates and type of discordance. Receiver operating characteristic (ROC) analysis and DeLong's test were also used to examine the effect of different tracers on the discordant rates.

RESULT:

Discordance was observed in 6.53% of cases (n=211), with VR+/CL- in 4.61% (n=149) and VR-/CL+ in 1.92% (n=62). VR+/CL- discordant cases had significantly fewer amyloid-positive cortical regions compared to both VR+/CL+ and VR-/CL+ cases. VR-/CL+ cases had a significantly higher WM uptake than VR-/CL- and VR+/CL- cases. Our findings revealed a relationship between WM uptake and rates and types of discordance. High WM uptake can erroneously lead to CL+, due to gray matter (GM) contamination from the WM, and VR- status, due to reduced contrast between WM and GM, resulting in VR-/CL+ cases. Conversely, low WM uptake can result in an underestimation of CL values, inaccurately classifying a scan as CL-, and at the same time, the increased contrast may result in a VR+, thereby increasing the occurrence of discordant VR+/CL- cases.

CONCLUSION:

Variations in WM uptake significantly contribute to discordances by introducing positive or negative bias in CL values and altering the GM to WM contrast, which forms the basis of the VR. Nevertheless, the rates of discordant cases are low and VR represents a robust and validated method to determine the presence of amyloid deposition. VR enables enrolling patients with amyloid beta pathology, as seen on amyloid PET scans, whereas CL scaling was developed to provide standardized units that more consistently characterize longitudinal amyloid‑β change. These findings reflect the complementary roles of VR and CL in amyloid PET evaluation, with implications for refining diagnostic accuracy and disease monitoring in AD clinical trials and practice.

2026-05-01·JOURNAL OF NUCLEAR CARDIOLOGY

An era of precision: Emerging, research, and adjunct radiotracers for nuclear imaging of cardiac amyloidosis

Review

作者: Martin, Emily B ; Wall, Jonathan S

Cardiac amyloidosis (CA) has rapidly transitioned from an underrecognized cause of heart failure to a treatable protein-misfolding cardiomyopathy, driven by advances in transthyretin (TTR) stabilization and gene silencing, and immunotherapy to control monoclonal light chain production. Noninvasive diagnosis of transthyretin cardiac amyloidosis (ATTR) using technetium-99m bone-avid scintigraphy is now routine, yet these tracers do not bind amyloid and offer limited amyloid specificity, quantification, or monitoring of response to therapy. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) agents that directly engage amyloid or key downstream processes (fibroblast activation, inflammation, denervation) may redefine the diagnostic algorithm, phenotyping, risk stratification, and longitudinal assessment. Among these, iodine [¹²⁴I]evuzamitide (AT-01), a radioiodinated, pan-amyloid-binding peptide targeting amyloid fibrils and amyloid associated heparan sulfate proteoglycans, has emerged as the first amyloid-specific PET radiotracer to receive U.S. FDA Breakthrough Therapy designation for CA and has completed a Phase 3 pivotal evaluation. [¹⁸F]Florbetaben is similarly poised in a pivotal Phase 3 study. Herein, we summarize 1) Emerging radiotracers primed for clinical availability, including the pan-amyloid peptide tracers, [¹²⁴I]evuzamitide and [^99mTc]p5+14, the stilbene-based small molecule [¹⁸F]florbetaben, and the protein-based radiotracer, [^99mTc]aprotinin; 2) Research-focused, Aβ amyloid radiotracers and their performance in CA ([¹¹C]PiB; [¹⁸F]florbetapir, [¹⁸F]flutemetamol; and newer [¹⁸F]florbetazine); and 3) Adjunct radiotracers for exploring myocardial microenvironment ([⁶⁸Ga]FAPI, and others), emphasizing rationale for use, opportunities, synergies, strengths, limitations, and regulatory status. Finally, we outline future research and molecular targets to elucidate the pathology and the impact of novel amyloid therapeutics as they become available.

2026-03-01·Journal of Nuclear Medicine Technology

Quantitative Amyloid Brain Imaging: A Literature Review of the Centiloid Scale in Alzheimer Disease Evaluation

Review

作者: York, Benjamin ; Doroudinia, Abtin ; Colletti, Patrick M

Amyloid PET has become a pivotal imaging biomarker for Alzheimer disease (AD), enabling in vivo detection and quantification of β-amyloid deposition. However, variability in quantitative measurements across tracers, scanners, and analysis methods has considerably limited direct comparison of amyloid burden between studies and centers. To address this issue, the Centiloid Project has been developed to provide a standardized quantitative scale for amyloid PET, harmonizing results across tracers and institutions. In this literature review, we aim to summarize current evidence on the development, validation, and clinical application of the Centiloid scale in amyloid PET imaging, emphasizing its methodologic foundations, tracer-specific conversions, and diagnostic thresholds. Methods: A literature review was conducted using PubMed, Scopus, and Embase databases from January 2015 through October 2025. Search terms included "amyloid PET," "Centiloid," "SUVR," and "Alzheimer disease." We reviewed articles with quantitative amyloid PET analyses and Centiloid conversion and studies which compared multiple tracers using MIMneuro software Centiloid calibration. Results: The Centiloid method demonstrates strong intertracer and interscanner harmonization when standardized to the ¹¹C-Pittsburgh compound B reference, with high correlation (r ² > 0.9) across ¹⁸F-labeled tracers, including florbetapir, flutemetamol, and florbetaben. Most articles identified a Centiloid threshold between 20 and 25 Centiloids as indicative of significant amyloid pathology. Implementation of the Centiloid framework improved comparability across clinical trials and longitudinal studies, facilitating integration into the AT(N) research framework. Conclusion: The Centiloid scale represents a critical advancement in quantitative amyloid PET imaging, providing a universal reference that enhances data reproducibility, cross-trial comparisons, and clinical decision-making. Continued work is needed to expand standardization for novel tracers and hybrid imaging systems, ensuring full clinical translation of this metric in dementia imaging.

123

项与氟[¹⁸F]贝他苯相关的新闻（医药）

2026-09-03

·先通医药

聚焦核医前沿，共话创新发展｜先通医药亮相CSNM 2026

点蓝色字关注“先通医药” 联系方式投资者关系：ir@sinotau.com 商务合作：bd@sinotau.com END 关于先通医药北京先通国际医药科技股份有限公司（简称“先通医药”），始创于2005年，是中国放射性药物市场的领跑者，具备从放射性核素开发及生产、放射性药物研发、制造及商业化的全行业价值链端对端能力。先通医药秉持“做好核药，惠及大众”的使命，立足中国，放眼世界，公司总部位于北京，在上海设有研发中心，在江苏、广东、四川建设有现代化放射性药物生产基地；同时，在美国设有分支机构。以未满足的临床需求为导向，先通医药重点布局神经退行性疾病、心血管疾病、肿瘤学三大领域，建立了全面、差异化及具有协同效应的产品矩阵，于放射性诊疗一体化方面具有巨大潜力。其中，欧韦宁®为近20年来中国首个获准上市的创新性PET示踪剂；处于不同阶段的多款产品管线广泛覆盖全球放射性药物创新靶点，彰显我们管线的强大竞争力，引领创新放射性药物发展新速度。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用“预期”、“相信”、“预测”、“期望”、“打算”及其他类似词语进行表述时，凡与本公司有关的，目的均是要指明其属前瞻性表述。本公司并无义务不断地更新这些预测性陈述。这些前瞻性表述乃基于本公司管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确定性及其他因素的影响，有些超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、中国政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司、本公司董事及雇员代理概不承担 (a) 更正或更新本新闻稿所载前瞻性表述之任何义务；及 (b) 倘因任何前瞻性表述不能实现或变成不正确。 ▲滑动查看更多

2026-08-27

·先通医药

四川先通医药顺利通过QES三体系认证

点蓝色字关注“先通医药” 近日，北京先通国际医药科技股份有限公司（以下简称“先通医药”）全资子公司——四川先通医药有限公司（以下简称“四川先通医药”）顺利取得了QES一体化管理体系认证证书。此次认证一次性覆盖ISO 9001质量管理体系、ISO 14001环境管理体系及ISO 45001职业健康安全管理体系（即“三标一体化”认证），标志着公司在质量管控、环境友好运营及员工职业健康安全保障方面，全面接轨国际通行的现代化管理标准。本次认证范围主要涵盖放射性药品经营及产品包装的放射性监测服务等相关活动。针对放射性药品流通中“高安全、高合规”的特殊属性，四川先通医药将三体系标准深度嵌入业务流程，围绕放射性药品入库、仓储、运输及包装监测等关键节点，构建起覆盖质量追溯、环境风险防控与职业安全防护的全过程管理机制。这不仅强化了对放射性物质潜在风险的综合管控能力，也为放射性药品流通环节的规范化操作树立了实践样本。本次认证既是对四川先通医药体系化运营能力的专业认可，也为公司拓展产业链合作、提升客户信任度提供了有力支撑。尤其在放射性药品供应链对安全性、稳定性要求日益提升的背景下，这一认证将有效支撑公司业务的高质量、可持续发展。放射性药品因其半衰期短、辐射防护要求高等特性，其流通与服务的规范化程度，直接关系到临床用药的安全与可及性。先通医药未来将持续完善覆盖研发、生产、流通及商业化全链条的质量与安全管理体系，以更严谨的体系和更专业的服务，协同行业伙伴共同推动中国放射性药物产业向标准化、规范化、专业化方向稳健发展。联系方式投资者关系：ir@sinotau.com 商务合作：bd@sinotau.com END 关于先通医药北京先通国际医药科技股份有限公司（简称“先通医药”），始创于2005年，是中国放射性药物市场的领跑者，具备从放射性核素开发及生产、放射性药物研发、制造及商业化的全行业价值链端对端能力。先通医药秉持“做好核药，惠及大众”的使命，立足中国，放眼世界，公司总部位于北京，在上海设有研发中心，在江苏、广东、四川建设有现代化放射性药物生产基地；同时，在美国设有分支机构。以未满足的临床需求为导向，先通医药重点布局神经退行性疾病、心血管疾病、肿瘤学三大领域，建立了全面、差异化及具有协同效应的产品矩阵，于放射性诊疗一体化方面具有巨大潜力。其中，欧韦宁®为近20年来中国首个获准上市的创新性PET示踪剂；处于不同阶段的多款产品管线广泛覆盖全球放射性药物创新靶点，彰显我们管线的强大竞争力，引领创新放射性药物发展新速度。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用“预期”、“相信”、“预测”、“期望”、“打算”及其他类似词语进行表述时，凡与本公司有关的，目的均是要指明其属前瞻性表述。本公司并无义务不断地更新这些预测性陈述。这些前瞻性表述乃基于本公司管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确定性及其他因素的影响，有些超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、中国政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司、本公司董事及雇员代理概不承担 (a) 更正或更新本新闻稿所载前瞻性表述之任何义务；及 (b) 倘因任何前瞻性表述不能实现或变成不正确。 ▲滑动查看更多

2026-08-18

·PRNewswire

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

COVINGTON, Ky., Aug. 18, 2026 /PRNewswire/ -- NeuroQuant ® PET has received FDA 510(k) clearance (K261916) for PET. NeuroQuant PET ® aids physicians in the evaluation of patient pathologies and the clinical interpretation of PET performed for the assessment of cognitive impairment and other neurological conditions. Continue Reading NeuroQuant ® PET by Cortechs.ai has received FDA 510(k) clearance (K261916) for PET. As molecular imaging plays an increasingly central role in the diagnosis and management of Alzheimer's disease and related neurodegenerative disorders, the demand for standardized, objective PET analysis continues to grow. NeuroQuant® PET is designed to deliver fully automated quantification, regional analysis, and structured reporting directly into routine clinical workflows. "Automated quantitative PET imaging represents the next frontier in precision and personalized medicine for Alzheimer's disease and related neurocognitive disorders. These new technological advancements are enabling the shift from phenotype-based assessment to a biological, biomarker-driven approach in assessing neurodegenerative disease. I am excited about the role NeuroQuant PET will play in shaping the future of how these conditions are understood and managed." said Dr. Ana Franceschi, M.D., Ph.D. The platform provides atlas-based quantification for amyloid PET tracers, generating standardized uptake value ratios (SUVRs) and structured reports to support consistent, data-driven interpretation. NeuroQuant® PET segments regions of interest and quantifies Centiloids for commonly used amyloid PET tracers flutemetamol, florbetaben, and florbetapir, enabling standardized comparison across tracers and imaging systems. Compatible with PET-CT, PET-MR, and PET-only workflows, NeuroQuant® PET features fully automated processing and PACS-ready outputs designed to integrate quantitative metrics into existing workflows. "NeuroQuant® PET reflects our commitment to advancing quantitative imaging in dementia care, giving clinicians objective, reproducible measurements they can trust, so patients get earlier answers and more confident treatment decisions" said Kyle Frye, CEO of Cortechs.ai. "With FDA 510(k)-clearance status, we look forward to expanding access to standardized PET quantification that supports precision medicine in Alzheimer's disease and related dementias." About Cortechs.ai Cortechs.ai is the leader in AI applications in radiology, leveraging advanced technologies in medical imaging to enhance disease screening and timely assessment, empowering healthcare providers to deliver better outcomes for patients. The company develops and markets innovative medical imaging solution software for assessing neurological disorders such as Alzheimer's disease, epilepsy, multiple sclerosis, brain trauma, tumors and prostate cancer, helping clinicians identify and monitor clinically significant cases. Cortechs.ai's industry-leading imaging solutions offer radiologists, oncologists, and urologists streamlined, cost-effective tools to assist in the assessment of brain and prostate health, including cancer evaluation. Visit  for additional insights and follow us on Twitter, LinkedIn, and Facebook. For more information, please contact: [email protected] +1 858 459 9700 SOURCE Cortechs.ai 21% more press release views with Request a Demo

100 项与氟[¹⁸F]贝他苯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	氟[¹⁸F]贝他苯	V09AX06	DB09148

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
阿尔茨海默症	美国	Lantheus Holdings, Inc.	2014-03-19
阿尔茨海默症	美国	Lantheus Medical Imaging, Inc.	2014-03-19
认知功能障碍	欧盟	Lantheus Holdings, Inc.	2014-02-20
认知功能障碍	冰岛	Lantheus Holdings, Inc.	2014-02-20
认知功能障碍	列支敦士登	Lantheus Holdings, Inc.	2014-02-20
认知功能障碍	挪威	Lantheus Holdings, Inc.	2014-02-20
诊断试剂	欧盟	Lantheus Holdings, Inc.	2014-02-20
诊断试剂	冰岛	Lantheus Holdings, Inc.	2014-02-20
诊断试剂	列支敦士登	Lantheus Holdings, Inc.	2014-02-20
诊断试剂	挪威	Lantheus Holdings, Inc.	2014-02-20

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
免疫球蛋白轻链淀粉样变性	临床3期	美国	Lantheus Holdings, Inc.	2023-01-13
免疫球蛋白轻链淀粉样变性	临床3期	德国	Lantheus Holdings, Inc.	2023-01-13
免疫球蛋白轻链淀粉样变性	临床3期	西班牙	Lantheus Holdings, Inc.	2023-01-13
免疫球蛋白轻链淀粉样变性	临床3期	英国	Lantheus Holdings, Inc.	2023-01-13
老年性心脏淀粉样变性	临床3期	美国	Lantheus Holdings, Inc.	2023-01-13
老年性心脏淀粉样变性	临床3期	德国	Lantheus Holdings, Inc.	2023-01-13
老年性心脏淀粉样变性	临床3期	西班牙	Lantheus Holdings, Inc.	2023-01-13
老年性心脏淀粉样变性	临床3期	英国	Lantheus Holdings, Inc.	2023-01-13
转甲状腺素蛋白淀粉样变性心肌病	临床3期	美国	Lantheus Holdings, Inc.	2023-01-13
转甲状腺素蛋白淀粉样变性心肌病	临床3期	德国	Lantheus Holdings, Inc.	2023-01-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03706261 (CTgov)	临床1期	阿尔茨海默症	145	18F-Florbetaben+18F-MK-6240	膚鏇鏇築範衊艱衊鹹製(繭遞鬱淵醖糧遞廠襯遞) = 獵壓襯壓餘齋鹹範淵獵範積觸積繭鑰壓淵繭選 (鏇鬱蓋觸膚淵製顧艱獵, 0.23) 更多	-	2025-08-01
NCT02831283 (CTgov)	临床2期	阿尔茨海默症 \| 炎症	60	11C-PBR28+18F-Florbetaben (Amyloid-positive With Cognitive Impairment (AD))	鬱願糧膚鏇鏇衊糧餘鹹(鬱膚淵淵膚餘鬱網鏇顧) = 簾積廠選廠鏇選廠積構窪願鬱遞簾齋廠願鏇選 (壓衊夢膚淵衊構膚淵襯, 0.18) 更多	-	2025-03-05
				11C-PBR28+18F-Florbetaben (Amyloid-positive Without Impairment (Preclinical AD))	鬱願糧膚鏇鏇衊糧餘鹹(鬱膚淵淵膚餘鬱網鏇顧) = 蓋鹹窪鑰淵醖憲繭鏇獵窪願鬱遞簾齋廠願鏇選 (壓衊夢膚淵衊構膚淵襯, 0.16) 更多
NCT01222351 (CTgov)	N/A	阿尔茨海默症 \| 认知功能障碍	161	BAY 94-9172 (Florbetaben)	積壓壓淵製淵蓋蓋鬱構 = 鹽鏇憲鏇簾範製艱艱製鬱憲襯繭齋獵網遞鏇廠 (鑰選艱蓋鬱餘鹽蓋鑰膚, 構壓遞餘製遞築製衊範 ~ 築鏇簾淵簾襯淵範廠廠) 更多	-	2024-05-06
NCT03744312 (CTgov)	临床1/2期	阿尔茨海默症 \| 炎症	9	Florbetaben+11C-ER176 (Cognitive Impairment)	簾憲壓壓齋選蓋艱鹹艱(窪簾遞觸膚齋積餘鬱網) = 簾繭夢鹹糧鬱齋築範鑰鑰壓願鹽顧積簾夢鬱範 (鹽鹹壓鹹網窪蓋齋憲鏇, 簾蓋鏇構鬱觸願選選鹽 ~ 鹹鹽醖衊醖憲憲範糧選) 更多	-	2023-09-13
				Florbetaben+11C-ER176 (No Cognitive Impairment)	簾憲壓壓齋選蓋艱鹹艱(窪簾遞觸膚齋積餘鬱網) = 壓窪獵觸壓窪壓繭糧餘鑰壓願鹽顧積簾夢鬱範 (鹽鹹壓鹹網窪蓋齋憲鏇, 膚廠鹹網簾構網積壓鹹 ~ 觸餘糧願構鑰構夢襯廠) 更多
NCT02681172 (CTgov)	临床4期	阿尔茨海默症	218	florbetaben	選選顧觸窪壓鑰鬱範製 = 淵蓋蓋艱餘夢壓築艱簾願艱糧餘壓鹹積鬱蓋鏇 (鹹網繭網築簾繭齋繭糧, 鏇鏇範艱遞範鹽餘獵醖 ~ 觸選鏇簾構齋壓鹹衊鏇) 更多	-	2018-11-02
NCT02681172 (AAIC2017)	临床4期	轻度痴呆	205	Florbetaben PET imaging	構構獵餘窪鑰窪選鹽壓(簾壓淵築窪遞膚遞淵鏇) = 艱夢窪窪齋願淵願遞繭夢獵積醖網積獵餘憲衊 (構艱憲艱憲醖齋壓艱鏇, 59.9 ~ 73.2) 更多	-	2017-07-01
NCT01020838 (Pubmed \| J Nucl Med)	临床3期	阿尔茨海默症 \| 脑淀粉样血管病	82	18F-Florbetaben (In-person-trained interpreters)	廠遞顧襯積蓋衊糧襯積(糧選鑰廠憲築積網觸願) = 觸夢壓鹽衊醖鹹構窪簾鹽夢襯鹽鏇築艱衊顧鬱 (窪憲膚網獵鹹簾鏇鏇觸 ) 更多	-	2016-06-01
				18F-Florbetaben (Electronic training method)	廠遞顧襯積蓋衊糧襯積(糧選鑰廠憲築積網觸願) = 糧憲積齋淵鬱淵廠壓願鹽夢襯鹽鏇築艱衊顧鬱 (窪憲膚網獵鹹簾鏇鏇觸 ) 更多
NCT01020838 (Pubmed \| Alzheimers Dement)	临床3期	阿尔茨海默症 β-amyloid-positive	216	Florbetaben PET imaging	夢製積廠襯顧憲蓋鹽壓(鹽糧憲衊積觸夢餘壓顧) = 製膚膚憲膚齋繭窪簾蓋壓獵淵鹹積構醖積鬱願 (蓋築醖積願壓蓋構齋繭, 93.8 ~ 100) 更多	-	2015-08-01
NCT01138111 (Pubmed \| J Neurol Neurosurg Psychiatry)	临床1期	阿尔茨海默症	45	18F-florbetaben (FBB+)	繭襯夢鏇獵淵窪築壓顧(衊獵齋觸選簾糧廠蓋願) = 範夢觸願積網築淵積積膚糧顧鹽膚築鬱窪選齋 (願簾壓鹽簾窪鹽蓋鏇鹹 ) 更多	-	2015-04-01
				18F-florbetaben (FBB-)	淵蓋膚選鏇蓋衊鬱鹹積(願觸艱鹽齋遞網壓構範) = 憲積衊艱衊廠網廠膚鑰壓構網鹹獵鏇衊積蓋糧 (膚構窪窪製艱襯製構網 )
AAIC2013	N/A	阿尔茨海默症	-	florbetaben (AD patients)	構窪憲範鏇網衊壓選積(鬱網蓋製鹹鬱遞獵醖窪) = 窪觸糧顧夢築願衊願繭鏇簾齋淵醖構遞衊壓獵 (簾鏇艱鏇網膚餘簾顧網, 0.77 ~ 0.86) 更多	-	2013-07-01
				florbetaben (Healthy volunteers)	衊築繭淵膚壓艱襯構願(構醖膚獵鑰網築製觸選) = 膚憲餘糧鏇範餘窪構鹹製膚製膚醖鹹壓鏇構願 (鬱襯簾夢製遞顧鏇壓鹹, 73.9 ~ 88.2)